Stifel Starts Akcea Therapeutics, Inc. (AKCA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
Cowen Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:42 AM EDTCowen initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating.
Analyst Eric Schmidt expects shares to outperform citing Volanesorsen commercialization and the advanced development of AKCEA-APO(a)-LRx, AKCEA-APOCIII-LRx, and AKCEA-ANGPTL3-LRx.
For an analyst ratings summary and... More
BMO Capital Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:11 AM EDTBMO Capital initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating and a price target of $25.00.
Analyst Do Kim expects Volanesorsen approval for familial chylomicronemia syndrome (FCS) sometime in H2 2018 and estimates WW peak sales could be $850 million assuming... More
Wells Fargo Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
August 8, 2017 5:09 AM EDTWells Fargo initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Outperform rating and a price target of $27.00.
Analyst Jim Birchenough sees a blockbuster opportunity for lead antisense oligonucleotide therapeutic Volanesoren in patients with familial chylomicronemia syndrome (FCS). The analyst believes the... More
